Jonathan T. Vu

Jonathan T. Vu

Auto-generated profile, based on publicly available information

Jonathan T. Vu

Interdisciplinary Quantitative Biosciences Program, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2019 in Science
Verified
Journal Article
Closed access
BWBeeke Wienert
Beeke Wienert
SWStacia K. Wyman
Stacia K. Wyman
CRChristopher D. Richardson
Christopher D. Richardson
CYCharles D. Yeh
Charles D. Yeh
PAPinar Akcakaya
Pinar Akcakaya
JCJacob E. Corn
Jacob E. Corn
Spotting off-targets from gene editing: Unintended genomic modifications limit the potential therapeutic use of gene-editing tools. Available methods to find off-targets generally do not work in vivo or detect single-nucleotide changes. Three papers in this issue report new methods for monitoring gene-editing tools in vivo (see the Perspective by Kempton and Qi). Wienert et al. followed the recruitment of a DNA repair protein to DNA breaks induced by CRISPR-Cas9, enabling unbiased detection of off-target editing in cellular and animal models. Zuo et al. identified off-targets without the interference of natural genetic heterogeneity by injecting base editors into one blastomere of a two-cell mouse embryo and leaving the other genetically identical blastomere unedited. Jin et al. performed whole-genome sequencing on individual, genome-edited rice plants to identify unintended mutations. Cytosine, but not adenine, base editors induced numerous single-nucleotide variants in both mouse and rice. Science , this issue p. 286 , p. 289 , p. 292 ; see also p. 234

1 September 2020 in Cell Reports
Verified
Journal Article
Open access
JSJiyung J. Shin
Jiyung J. Shin
MSMarkus S. Schröder
Markus S. Schröder
FCFrancisco Caiado
Francisco Caiado
SWStacia K. Wyman
Stacia K. Wyman
NBNicolas L. Bray
Nicolas L. Bray
JCJacob E. Corn
Jacob E. Corn
Genome editing often takes the form of either error-prone sequence disruption by non-homologous end joining (NHEJ) or sequence replacement by homology-directed repair (HDR). Although NHEJ is generally effective, HDR is often difficult in primary cells. Here, we use a combination of immunophenotyping, next-generation sequencing, and single-cell RNA sequencing to investigate and reprogram genome editing outcomes in subpopulations of adult hematopoietic stem and progenitor cells. We find that although quiescent stem-enriched cells mostly use NHEJ, non-quiescent cells with the same immunophenotype use both NHEJ and HDR. Inducing quiescence before editing results in a loss of HDR in all cell subtypes. We develop a strategy of controlled cycling and quiescence that yields a 6-fold increase in the HDR/NHEJ ratio in quiescent stem cells ex vivo and in vivo. Our results highlight the tension between editing and cellular physiology and suggest strategies to manipulate quiescent cells for research and therapeutic genome editing.

11 February 2022 in eLife
Verified
Journal Article
Open access
NRNithin Sam Ravi
Nithin Sam Ravi
BWBeeke Wienert
Beeke Wienert
SWStacia K Wyman
Stacia K Wyman
HBHenry William Bell
Henry William Bell
AGAnila George
Anila George
KMKumarasamypet M Mohankumar
Kumarasamypet M Mohankumar
Naturally occurring point mutations in the HBG promoter switch hemoglobin synthesis from defective adult beta-globin to fetal gamma-globin in sickle cell patients with hereditary persistence of fetal hemoglobin (HPFH) and ameliorate the clinical severity. Inspired by this natural phenomenon, we tiled the highly homologous HBG proximal promoters using adenine and cytosine base editors that avoid the generation of large deletions and identified novel regulatory regions including a cluster at the –123 region. Base editing at –123 and –124 bp of HBG promoter induced fetal hemoglobin (HbF) to a higher level than disruption of well-known BCL11A binding site in erythroblasts derived from human CD34+ hematopoietic stem and progenitor cells (HSPC). We further demonstrated in vitro that the introduction of –123T > C and –124T > C HPFH-like mutations drives gamma-globin expression by creating a de novo binding site for KLF1. Overall, our findings shed light on so far unknown regulatory elements within the HBG promoter and identified additional targets for therapeutic upregulation of fetal hemoglobin.

1 July 2020 in Molecular Cell
Verified
Journal Article
Closed access
AWAlan S. Wang
Alan S. Wang
LCLeo C. Chen
Leo C. Chen
RWR. Alex Wu
R. Alex Wu
YHYvonne Hao
Yvonne Hao
DMDavid T. McSwiggen
David T. McSwiggen
JCJacob E. Corn
Jacob E. Corn

15 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJennifer E Chung
Jennifer E Chung
WMWendy Magis
Wendy Magis
JVJonathan Vu
Jonathan Vu
SHSeok-Jin Heo
Seok-Jin Heo
KWKirmo Wartiovaara
Kirmo Wartiovaara
MDMark A DeWitt
Mark A DeWitt
Sickle Cell Disease and ß-thalassemia, which are caused by defective or deficient adult ß-globin (HBB) respectively, are the most common serious genetic blood diseases in the world. Persistent expression of the fetal ß-like globin, also known as 𝛾-globin, can ameliorate both disorders by serving in place of the adult ß-globin as a part of the fetal hemoglobin tetramer (HbF). Here we use CRISPR-Cas9 gene editing to explore a potential 𝛾-globin silencer region upstream of the δ-globin gene identified by comparison of naturally-occurring deletion mutations associated with up-regulated 𝛾-globin. We find that deletion of a 1.7 kb consensus element or select 350 bp sub-regions from bulk populations of cells increases levels of HbF. Screening of individual sgRNAs in one sub-region revealed three single guides that caused increases in 𝛾-globin expression. Deletion of the 1.7 kb region in HUDEP-2 clonal sublines, and in colonies derived from CD34+ hematopoietic stem/progenitor cells (HSPCs), does not cause significant up-regulation of 𝛾-globin. These data suggest that the 1.7 kb region is not an autonomous 𝛾-globin silencer, and thus by itself is not a suitable therapeutic target for gene editing treatment of ß-hemoglobinopathies.

18 June 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
SCSamuel C. Curran
Samuel C. Curran
AHAndrew Hagen
Andrew Hagen
SPSean Poust
Sean Poust
LCLeanne Jade G. Chan
Leanne Jade G. Chan
BGBrett M. Garabedian
Brett M. Garabedian
JKJay D. Keasling
Jay D. Keasling